Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linsitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R known ✓ | P08069 | 16/20 | 1.00 |
| ▸ | INSR known ✓ | P06213 | 2/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | INSRR | P14616 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linsitinib SCHEMBL400735 | 1.00 | IGF1R (1.00) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL400369 | 1.00 | IGF1R (1.00) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL29392484 | 1.00 | IGF1R (1.00) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL10255925 | 1.00 | IGF1R (1.00) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL528638 | 0.99 | IGF1R (0.98) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL528637 | 0.99 | IGF1R (0.98) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL14937815 | 0.96 | IGF1R (0.92) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL14937816 | 0.96 | IGF1R (0.92) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL1758871 | 0.96 | IGF1R (0.92) | IGF1RINSRMAPK3MAPK1RIPK2 | |
| Linsitinib SCHEMBL14938209 | 0.95 | IGF1R (0.90) | IGF1RINSRMAPK3MAPK1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| WO-2017097865-A9 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-08-31 | — | — | WO | claimed |
| WO-2017097865-A1 | COMBINATION OF CALORIC RESTRICTION (CR) OR IGF1/INSULIN RECEPTOR INHIBITOR WITH LSD1 INHIBITOR | ISTITUTO EUROPEO DI ONCOLOGIA (IT) | 2017-06-15 | — | — | WO | claimed |
| WO-2016007945-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CARDIAC HYPERTROPHY | GENESYS RESEARCH INSTITUTE (US) | 2016-01-14 | — | — | WO | claimed |
| US-8575164-B2 | Combination cancer therapy | OSI Pharmaceuticals, LLC (US) | 2013-11-05 | — | — | US | claimed |
| US-20120101084-A1 | Biological Markers Predictive of Anti-Cancer Response to Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-04-26 | — | — | US | claimed |
| EP-2305682-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | claimed |
| EP-2131836-A1 | COMBINATION OF IMIDAZO Ý1,5-A¨PYRAZINYL DERIVATIVES WITH AN AGENT THAT INHIBITS SERINE PHOSPHORYLATION OF IRS1 FOR USE IN THE TREATMENT OF CANCER | OSI Pharmaceuticals, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| EP-1740591-B1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-20080267957-A1 | Combination cancer therapy | OSI PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | claimed |
| WO-2008106168-A1 | COMBINATION OF IMIDAZO [1,5-A] PYRAZINYL DERIVATIVES WITH AN AGENT THAT INHIBITS SERINE PHOSPHORYLATION OF IRS1 FOR USE IN THE TREATMENT OF CANCER | OSI PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| EP-4731628-A1 | CRYSTALLINE SALTS OF LINSITINIB FOR TREATING THYROID EYE DISEASE | Sling Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1740591-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| WO-2005097800-A1 | 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101084-A1 | Biological Markers Predictive of Anti-Cancer Response to Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors | IGF1R, IGFBP3, IGFBP1 | IGF1R 1/4885INSR 7/4885MAPK3 65/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | IGF1R 573/4885INSR 2263/4885MAPK3 565/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | IGF1R 721/4885INSR 2203/4885MAPK3 1395/4885 |
| US-20080267957-A1 | Combination cancer therapy | IGF1R, IGFBP4, IGFBP1 | IGF1R 1/4885INSR 10/4885MAPK3 898/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | IGF1R 1/4885INSR 27/4885MAPK3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.